Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Related Citations for PubMed (Select 8285810)

1.

A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis.

Rochon PA, Gurwitz JH, Simms RW, Fortin PR, Felson DT, Minaker KL, Chalmers TC.

Arch Intern Med. 1994 Jan 24;154(2):157-63.

PMID:
8285810
2.

Valdecoxib: a review.

Chavez ML, DeKorte CJ.

Clin Ther. 2003 Mar;25(3):817-51. Review.

PMID:
12852704
3.

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

Hochberg MC.

Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):4-14. Review.

PMID:
12528069
4.

The causes and effects of socio-demographic exclusions from clinical trials.

Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, Dieppe P.

Health Technol Assess. 2005 Oct;9(38):iii-iv, ix-x, 1-152. Review.

5.

Are randomized control trial outcomes influenced by the inclusion of a placebo group?: a systematic review of nonsteroidal antiinflammatory drug trials for arthritis treatment.

Rochon PA, Binns MA, Litner JA, Litner GM, Fischbach MS, Eisenberg D, Kaptchuk TJ, Stason WB, Chalmers TC.

J Clin Epidemiol. 1999 Feb;52(2):113-22. Review.

PMID:
10201651
6.

Reporting of age data in clinical trials of arthritis. Deficiencies and solutions.

Rochon PA, Fortin PR, Dear KB, Minaker KL, Chalmers TC.

Arch Intern Med. 1993 Jan 25;153(2):243-8.

PMID:
8422212
7.

Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review.

Emery P, Kong SX, Ehrich EW, Watson DJ, Towheed TE.

Clin Ther. 2002 Aug;24(8):1225-91. Review.

PMID:
12240779
8.

A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.

Choy EH, Smith C, Doré CJ, Scott DL.

Rheumatology (Oxford). 2005 Nov;44(11):1414-21. Epub 2005 Jul 19. Review.

9.

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.

Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.

Clin Ther. 2005 Aug;27(8):1196-214. Review.

PMID:
16199245
10.

What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

Hochberg MC.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Review.

PMID:
11695246
13.

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.

Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee.

Lancet. 2006 Nov 18;368(9549):1771-81.

PMID:
17113426
14.
17.

Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits.

Gomez Cerezo J, Lubomirov Hristov R, Carcas Sansuán AJ, Vázquez Rodríguez JJ.

Eur J Clin Pharmacol. 2003 Jun;59(2):169-75. Epub 2003 Apr 16.

PMID:
12698301
18.
19.

[Meta-analysis on the effect and adverse reaction on patients with osteoarthritis and rheumatoid arthritis treated with non-steroidal anti-inflammatory drugs].

Shi W, Wang YM, Cheng NN, Chen BY, Li D.

Zhonghua Liu Xing Bing Xue Za Zhi. 2003 Nov;24(11):1044-8. Chinese.

PMID:
14687510
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk